Introduction:
The biologics market in China is rapidly expanding, with a growing demand for innovative treatments and therapies. In 2026, China is set to emerge as a key player in the global biologics industry. With a focus on research and development, China is poised to become a leading producer and exporter of biologics in the coming years. According to industry reports, the production volume of biologics in China is expected to double by 2026, making it a top player in the market.
Top 10 Biologics Rapid Response in China 2026:
1. Sinopharm Group
– Sinopharm Group is a leading biologics company in China, with a market share of over 20%. The company has been at the forefront of research and development in the biologics sector, focusing on innovative treatments for a wide range of diseases.
2. Shenzhen Kangtai Biological Products Co., Ltd.
– Shenzhen Kangtai Biological Products Co., Ltd. is a key player in the biologics market in China, with a production volume of over 100,000 units per year. The company has a strong focus on vaccine development and has been expanding its presence in the global market.
3. Shanghai Fosun Pharmaceutical Group Co., Ltd.
– Shanghai Fosun Pharmaceutical Group Co., Ltd. is a major player in the biologics industry in China, with a market share of over 15%. The company has a diverse portfolio of biologics products, ranging from vaccines to monoclonal antibodies.
4. Beijing Tiantan Biological Products Co., Ltd.
– Beijing Tiantan Biological Products Co., Ltd. is a leading biologics company in China, with a production volume of over 50,000 units per year. The company specializes in the development of vaccines and has a strong presence in the domestic market.
5. Harbin Pharmaceutical Group Co., Ltd.
– Harbin Pharmaceutical Group Co., Ltd. is a key player in the biologics market in China, with a market share of over 10%. The company has been focusing on the development of innovative biologics products for a wide range of therapeutic areas.
6. Jiangsu Hengrui Medicine Co., Ltd.
– Jiangsu Hengrui Medicine Co., Ltd. is a major player in the biologics industry in China, with a production volume of over 80,000 units per year. The company has a strong focus on research and development, with a pipeline of innovative biologics products.
7. Zhejiang Huahai Pharmaceutical Co., Ltd.
– Zhejiang Huahai Pharmaceutical Co., Ltd. is a leading biologics company in China, with a market share of over 12%. The company has been expanding its presence in the global market, with a focus on the development of biosimilar products.
8. Sino Biopharmaceutical Limited
– Sino Biopharmaceutical Limited is a key player in the biologics market in China, with a production volume of over 60,000 units per year. The company has a diverse portfolio of biologics products, ranging from vaccines to monoclonal antibodies.
9. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
– Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. is a major player in the biologics industry in China, with a market share of over 8%. The company has been focusing on the development of innovative biologics products for a wide range of therapeutic areas.
10. Chongqing Zhifei Biological Products Co., Ltd.
– Chongqing Zhifei Biological Products Co., Ltd. is a leading biologics company in China, with a production volume of over 40,000 units per year. The company specializes in the development of vaccines and has a strong presence in the domestic market.
Insights:
The biologics market in China is poised for rapid growth in the coming years, with a focus on innovation and research and development. By 2026, China is expected to emerge as a key player in the global biologics industry, with a significant increase in production volume and market share. With a growing demand for innovative treatments and therapies, Chinese biologics companies are well-positioned to capitalize on this trend and become major players in the global market. According to industry forecasts, the biologics market in China is set to double in size by 2026, making it a top destination for investment and collaboration in the biologics sector.
Related Analysis: View Previous Industry Report
